Aerovate Therapeutics, Inc. (AVTE)
9.80
0.00 (0.00%)
Inactive · Last trade price
on Apr 28, 2025
Aerovate Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Aerovate Therapeutics stock had an average target of 11.75, with a low estimate of 2.00 and a high estimate of 41.
Analyst Consensus: Hold
* Price targets were last updated on Jun 18, 2024.
Analyst Ratings
The average analyst rating for Aerovate Therapeutics stock from 7 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 1 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 1 | 2 | 3 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI Group | Evercore ISI Group | Buy → Hold Downgrades $27 → $2 | Buy → Hold | Downgrades | $27 → $2 | -79.59% | Jun 18, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 18, 2024 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $35 → $2 | Buy → Hold | Downgrades | $35 → $2 | -79.59% | Jun 18, 2024 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jun 18, 2024 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $65 → $2 | Strong Buy → Hold | Downgrades | $65 → $2 | -79.59% | Jun 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.63
from -2.44
EPS Next Year
-2.51
from -0.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.18 | -1.67 | -0.74 |
| Avg | -0.63 | -2.51 | -0.71 |
| Low | -1.11 | -3.27 | -0.69 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.